8-K: BioSig Technologies Closes $15M Public Offering

BioSig Technologies, Inc. successfully closed its underwritten public offering, raising approximately $15 million to fund strategic initiatives including gold bullion purchases and Streamex's operational build-out.

Summary

• BioSig Technologies, Inc. (BSGM) completed an underwritten public offering, selling 3,852,149 shares of common stock at $3.90 per share.
• The offering, which closed on August 15, 2025, generated gross proceeds of approximately $15,023,381.10 before deducting underwriting discounts and other estimated offering expenses.
• Net proceeds are intended for purchasing gold bullion in accordance with the company's investment policy, for working capital, and for general corporate purposes.
• The offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276298) declared effective on December 17, 2024.
• Underwriting discounts and commissions were 6.0%, or $0.234 per share.
• The company, its officers, directors, and certain stockholders are subject to 90-day lock-up agreements following the date of the Underwriting Agreement.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a capital raise inherently involves dilution, the successful closing of a significant offering, the strategic allocation of funds towards growth areas like gold tokenization, and the favorable terms (no warrants) are positive. However, the disclosed material weaknesses in internal controls present a notable concern.

Positives

• Successfully closed a public offering, securing approximately $15 million in gross proceeds to bolster financial resources.
• The offering was structured without pre-funded warrants, which is generally favorable for existing shareholders.
• Proceeds are allocated to strategic investments, including gold bullion purchases and the operational build-out of Streamex, aligning with the company's investment policy and growth strategy.
• Management expressed confidence that the capital raise will enable accelerated shareholder value creation and support the company's goal of becoming a Nasdaq-listed leader in the gold bullion-based real-world asset space.

Negatives

• The public offering of new shares will result in dilution for existing shareholders.
• The company disclosed material weaknesses in its internal control over financial reporting and disclosure controls as of December 31, 2024, which are still in the process of remediation.

Risks

• The company may not have sufficient resources to fund its business and may need to issue additional debt or equity.
• Risks are involved in properly managing complex projects.
• Uncertainty exists regarding the company's ability to continue implementing its strategy, including having sufficient financial resources.
• There are risks related to whether the company will be able to realize the benefits of the acquisition of Streamex.
• Shareholder approval of the Streamex acquisition and recently announced convertible debenture financing and standby equity purchase agreement may not be obtained.
• The company faces risks in maintaining compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise.
• Other risks and uncertainties are disclosed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital, and for general corporate purposes. Management anticipates that this capital raise will accelerate Streamex's operational build-out and enable a focus on accelerated shareholder value creation, aiming to establish the company as a Nasdaq-listed leader in the gold bullion-based real-world asset space.

Management Comments

• "We now have been able to marry a short and long-term capital strategy for the company with high-quality shareholders to support this pivotal point in our development."
• "We are building a Nasdaq-listed leader in the gold bullion based real world asset space and we can now focus on accelerated shareholder value creation."

Industry Context

This capital raise positions BioSig Technologies, through its recent merger with Streamex, to expand its presence in the emerging Real World Asset (RWA) and gold tokenization market. This sector aims to bring traditional assets like gold onto blockchain platforms, potentially increasing liquidity and accessibility. The company's dual focus on medical device technology (PURE EP Platform) and RWA tokenization suggests a diversified strategy, with the capital raise specifically targeting the growth of the Streamex gold tokenization business.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the offering's terms or the company's performance against global benchmarks.
• The absence of pre-funded warrants in the offering structure is a positive term for existing shareholders compared to offerings that include such dilutive instruments.

Corporate Governance

Legal Proceedings

• No legal or governmental proceeding is pending or threatened that is required to be described or that could reasonably be expected to have a Material Adverse Effect.

Stakeholder Impact

• **Shareholders**: Experience dilution from the issuance of new shares, but benefit from increased capital for strategic growth and the absence of pre-funded warrants. The 90-day lock-up period for insiders aims to stabilize the stock post-offering.
• **Employees**: The capital raise supports the company's operational build-out, potentially leading to job stability or growth opportunities, particularly within the Streamex subsidiary.
• **Customers**: Enhanced financial stability and investment in the Streamex platform could lead to improved products and services, especially in the gold tokenization space.
• **Creditors**: Improved liquidity and a stronger balance sheet from the capital raise could reduce credit risk.
• **Regulatory Authorities**: The company continues to comply with SEC filing requirements and Nasdaq listing criteria, with ongoing efforts to address internal control weaknesses.

Next Steps

• Purchase gold bullion in accordance with the company's investment policy.
• Allocate funds for working capital and general corporate purposes.
• Accelerate Streamex's operational build-out.
• Continue efforts to remediate material weaknesses in internal control over financial reporting and disclosure controls.

Key Dates

Recommendation

The successful closing of the $15 million public offering provides BioSig with crucial capital for its strategic initiatives, particularly the expansion of its Streamex gold tokenization business. The absence of pre-funded warrants is a positive structural aspect of the raise. However, the disclosed material weaknesses in internal controls over financial reporting, while being remediated, introduce a degree of uncertainty. Given the dilutive nature of the offering and the mixed signals from strategic growth potential versus internal control issues, a 'hold' recommendation is appropriate. Investors should monitor the progress of Streamex's build-out and the remediation of internal control weaknesses for future re-evaluation.

Keywords

Public Offering, Common Stock, Capital Raise, Underwriting Agreement, SEC Filing, BioSig Technologies, Streamex, Gold Tokenization, Real World Assets, Medical Device Technology, PURE EP Platform, Cardiovascular Arrhythmias, Nasdaq